SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

10 Aug 2022 Evaluate
The Sales for the quarter ended June 2022 of Rs. 1309.88 millions rose by 37.11% from Rs. 955.37 millions.The Net Loss for the quarter ended June 2022 is Rs. -140.88 millions as compared to Net Loss of Rs. -234.18 millions of corresponding quarter ended June 2021Operating profit for the quarter ended June 2022 rose to 153.81 millions as compared to 75.69 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1309.88 955.37 37.11 1309.88 955.37 37.11 5569.74 4506.95 23.58
Other Income 29.31 31.23 -6.15 29.31 31.23 -6.15 90.03 64.61 39.34
PBIDT 153.81 75.69 103.21 153.81 75.69 103.21 662.62 643.62 2.95
Interest 78.40 108.79 -27.93 78.40 108.79 -27.93 320.12 513.36 -37.64
PBDT 75.41 -33.10 -327.82 75.41 -33.10 -327.82 342.50 130.26 162.94
Depreciation 216.29 201.08 7.56 216.29 201.08 7.56 870.21 1088.99 -20.09
PBT -140.88 -234.18 -39.84 -140.88 -234.18 -39.84 -527.71 -958.73 -44.96
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -140.88 -234.18 -39.84 -140.88 -234.18 -39.84 -527.71 -958.73 -44.96
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 11.74 7.92 48.21 11.74 7.92 48.21 11.90 14.28 -16.69

Orchid Pharma Share Price

1007.85 -42.85 (-4.08%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: